Matter Neuroscience

Market position

Matter positions itself as a consumer biotech company at the intersection of neuroscience research and consumer well-being apps, distinguishing itself from conventional mental-health or wellness software by grounding its product in fMRI and molecular neuroscience studies and by pursuing a biomarker for happiness. It cites a mental health context of over 200 million people living with major depressive disorders.

Differentiators cited by the company include a research-derived product (the consumer app is the same tool used in clinical studies), academic partnerships with Maastricht University, the Happiness Research Institute and the Icahn School of Medicine at Mount Sinai, a scientific and clinical advisory board of academic neuroscientists and radiologists, a focus on positive emotions and their neurotransmitter basis rather than treating pathology, and explicitly anti-engagement design and privacy commitments (defined session stopping points, no model training on user data, on-device decryption of photos).

Technology

Matter's approach combines molecular neuroscience, ultra-high-field fMRI brain imaging and subjective emotional training, together with AI-based coaching. Studies with Maastricht University's Brain Imaging Center use fMRI to monitor continuous brain activity and map which brain regions activate with specific positive emotions, with the app used to stimulate positive emotions and deliver personalized recommendations. The app links logged positive memories to six neurotransmitters/hormones and produces a "Matter score." The company states that user data is not used to train foundation models and that personal photos are decrypted only on the user's device.

Go-to-market

Matter built its technology inside clinical studies and then released the same app directly to consumers, initially as a public beta promoted via its website and social channels (Instagram, TikTok). It emerged from stealth with a coordinated press announcement in February 2024 and markets the app around a community ("the world's first emotional fitness community"), user testimonials, and published study results.

Interested, healthy consumers seeking to improve subjective well-being and emotional awareness; clinical study participants; and, potentially, pharmaceutical companies as buyers of biomarker research findings.

Geography

Headquartered in New York City, with research collaborations in the Netherlands (Maastricht University Brain Imaging Center), Denmark-based Happiness Research Institute, the Icahn School of Medicine at Mount Sinai in New York, and an advisory board member at University Hospitals Tübingen in Germany. Study results were slated for presentation in Seoul, South Korea.

History

Founded in 2019, Matter spent roughly three years in stealth running clinical studies in brain imaging and happiness research with academic partners. Bouchon joined ARCH Venture Partners as a venture partner in 2021 to advise on neuroscience deals, the same year Chris Shiflett joined as co-founder. In February 2024 the company emerged from stealth with $26 million in total funding and released a public beta of its consumer iOS app. It planned three additional clinical studies in 2024 and to present high-field fMRI results at the 2024 Organization for Human Brain Mapping Annual Meeting in Seoul. In 2025 it ran a wintertime randomized cross-over study with the Happiness Research Institute, and its current site describes an AI coach ("M") and community features.

Risks & controversies

Key uncertainties include the unproven core scientific premise — a universal biomarker for happiness had not been identified as of the sources, and full study data and analysis from the Maastricht fMRI work was only expected later in 2024. The company had no confirmed revenue model at launch, with subscriptions described only as a possibility, and its potential pharma-licensing upside is contingent on research success. Efficacy claims rest largely on company-reported studies with academic partners rather than independently published results in the material available. Business Insider published a correction to its coverage regarding which firms led the Series A and the company's name in the headline.